CXCL2 and non-small cell lung carcinoma: Differential expression of CXCL2 was validated at single- and bulk-cell resolutions using Fluidigm 3′-end scRNA-seq and qRT-PCR analyses, respectively, in the four human NSCLC epithelial cell lines (Fig. 4a), 34 early-stage LUAD patients (Fig. 5b) and a various cell population of 58 multiple-stage LUAD patients using the 10x Genomics 3′-end scRNA-seq dataset (Fig. 7d).